Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 75.19M P/E - EPS this Y 55.00% Ern Qtrly Grth -
Income -12.75M Forward P/E -3.33 EPS next Y -22.20% 50D Avg Chg -25.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -24.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -63.00%
Recommedations 1.50 Quick Ratio 0.46 Shares Outstanding 5.32M 52W Low Chg 59.00%
Insider Own - ROA -178.20% Shares Float 4.27M Beta 0.34
Inst Own - ROE - Shares Shorted/Prior 93.27K/107.86K Price 1.73
Gross Margin - Profit Margin - Avg. Volume 229,796 Target Price 51.90
Oper. Margin - Earnings Date Nov 5 Volume 85,316 Change -0.57%
About Brainstorm Cell Therapeutics In

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Brainstorm Cell Therapeutics In News
12/09/24 BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update
12/03/24 BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
12/02/24 BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024
11/14/24 BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
11/11/24 BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
10/30/24 BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
10/28/24 BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting
10/07/24 BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit
05:00 AM BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting
09/16/24 Life Sciences Virtual Investor Forum Agenda Announced for September 19th
08/19/24 BCLI: SPA in Place for Phase 3b Trial of NurOwn® in ALS…
08/14/24 BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
08/07/24 BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update
07:30 AM BCLI Update - Progress Supports Our 10x Plus Value Range Potential
07/10/24 BCLI: Preparing to Initiate Phase 3b Trial of NurOwn™ Before End of 2024…
07/01/24 BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program
06/27/24 BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
06/26/24 BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
06/20/24 BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
06/14/24 BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
BCLI Chatroom

User Image steven_glandsberg Posted - 1 hour ago

$BCLI I no doubt have faith in nurown, the product….HOWEVER, it’s absolutely comical how in hindsight, like 98% of what chaim has said over the past 8 years I’ve been invested here has been complete bullshit. Guy is a total bean bag

User Image neuroinvestor3 Posted - 2 hours ago

@D0C_H0LLIDAY $NRSN looks similar regarding ALS survival benefit. Could be complementary treatments. Add in $BCLI and PALS will live a lot longer! $CLNN's real revenue is going to come from MS and eventually, as a prophylactic against all neurodegenerative conditions.

User Image Travelling Posted - 3 hours ago

$CADL Buying to hold (buyout candidate imho, like $esta), watching $nrxp $bcli

User Image funnymoney90210 Posted - 3 hours ago

$BCLI $14 Easy for sure

User Image thres Posted - 7 hours ago

$BCLI The good news is 2025 Will be the Year of Nurown Clinical Phase 3B trial , a possible BLA application after Part A will speed things up as discussed at the Webinar: 11Dec24 ALS Webimar https://lifescievents-com/event/brainstorm/ @ 38.15 Describing the slide below, BCLI CMO Dr Bob Dahger said “Upon successful completion of Part A (Double-Blind) of the Phase 3b Study, we will be positioned to submit our Biologic License Application (for Regulatory Approval, potentially accelerating our path to market”

User Image Winning_calls Posted - 1 day ago

$BCLI 😘😘😘

User Image Winning_calls Posted - 1 day ago

$BCLI pick me up @ $2.32♡

User Image funnymoney90210 Posted - 2 days ago

$BCLI reasy to blast off

User Image Condo3e Posted - 2 days ago

$BCLI So here's a question, Neurosense is getting some positive billion-dollar value comments for their ALS therapy, any thoughts on whether it has greater potential than NurOwn.

User Image ALSCellTherapy Posted - 2 days ago

$BCLI Brainstorm met with the FDA in person a couple of times once to hammer out the SPA agreement on the parameters for the trial and once for CMC manufacturing. Brainstorm announced both publicly. But Irish coffee and his buddies deny all of this. LMAO. Ask yourself who has an agenda?

User Image ALSCellTherapy Posted - 2 days ago

$BCLI Irish and friends. You guys have made these same points here now how many times. If you don't have an agenda can you give it a rest now? If you keep making the same points and doing the same dance here then I guess that shows your true agenda and motives.

User Image dvddc Posted - 3 days ago

$BCLI Irish is right. Us longs got kicked in the nuts a year ago. WE all thought we had a slam dunk. Now we are running out of cash and don't really know if BCLI has satisfied any of the FDA's concerns. Either way I still think we have a long road ahead.

User Image IrishSean Posted - 3 days ago

$BCLI @afc2881 If you took a little time and applied some intellect you would discern my post was a pros and cons regarding Brainstorm. I don’t want to waste too much of my time replying, however I’m not a denier. That said the word denier is not an investor term, it’s closer to herd mentality, blind unquestioning and displays bias, albeit unintentional I am sure on the part of some. I am invested heavily in this stock, but I’m not blind to the substantial risks. New investors should do their due diligence and make a non emotional decision. All the hand wringing, conspiracy, cult language is nonsense. Blind faith has no place when investing. I’m invested however I see the downside and comfortable with that financial threat. You would rather shout people down and not evaluate the investment decision. That is quite foolish if not dishonest, uninformed or misguided, take your pick.

User Image afc2881 Posted - 3 days ago

$BCLI Irish, we now know your ulterior motive here. You first come across as a concerned investor questioning management's actions after the sham adcom, the rs that "we" all felt, the path to funding that is taking longer than we like & anticipated & now bashing the Spa. Bcli & the Fda have both signed off on the requirements & parameters of the spa. The entry requirements for the trial are all set. The trial will happen. Chaim will get Nurown to market with the successful Ph3b. Enough of your negative bashing.

User Image ALSCellTherapy Posted - 3 days ago

$BCLI This is clearly setting up for that $5-$10+ run. Warrants will trigger at $6 and will cause additional demand and buying pressure.

User Image ALSCellTherapy Posted - 3 days ago

$BCLI Hedge and big funds are here and moving the stock. Stock is up 85% in the last month. That doesn't happen without these players like Little Sean.

User Image ALSCellTherapy Posted - 3 days ago

$BCLI People stock is moving up for a reason. Don't miss da boat! Irish Sean and his crew are just trying to rob your stock and shares and keep you from investing. It is something called soft bashing.

User Image ALSCellTherapy Posted - 3 days ago

$BCLI Irish Sean like just shut up already. Your stick and motivations are crystal clear here. Stock is moving up for a reason. Honestly get a life. You and your group are a stain to ALS patients and their families. Shame on you guys! It will catch up to you! Karma is coming for you!

User Image IrishSean Posted - 3 days ago

$BCLI Supporting Reg approvals: The SPA agreement suggests the FDA is willing to reevaluate efficacy and safety under clearly defined parameters. Subgroup analysis in the prior Phase 3 trial showed potential efficacy in a subset of patients with less severe ALS. Unmet Medical Need. Challenges: Nurown failed to meet its primary efficacy endpoints in the Phase. FDA’s advisory committee vote (17-1 against efficacy in September 2023) underscores skepticism about the data. Issues with consistent production and delivery of high quality mesenchymal cells. Even with the SPA success is not guaranteed. If the new trial does not produce statistically significant results approval is unlikely. Subgroups carry inherent risks of bias and replication of results in a prospective trial is not assured.

User Image IrishSean Posted - 3 days ago

$BCLI December call should deliver details on the cash runway, funding status and any financial challenges the business faces plus plans for capital raising or partnerships if any. Then milestones for 2025 and schedule tracking. Will investors get the above I wonder or more promises. The RS is still a bitter pill. Last resort BS that was peddled previously makes me quite distrustful of the CEO. Prefer honesty.

User Image Travelling Posted - 4 days ago

$DATS bought some more to hold, sold some $hsdt buying dips, holding $bb $fcel $bcli

User Image donkeydink Posted - 4 days ago

$BCLI strong 💪🏼

User Image dejkos Posted - 4 days ago

$PLUG up 10$ $BCLI up 14$

User Image dejkos Posted - 4 days ago

$BCLI The share's growth will continue until December 30. With good news, we can quickly reach $5+

User Image Strout100 Posted - 4 days ago

$BCLI Every f ing thing being said here was said 10 years ago, 5 years ago, and again now. History does repeat itself!

User Image Pipemajors82 Posted - 4 days ago

$BCLI https://www.facebook.com/share/v/xGaYohHQS7FE6SYX/

User Image EpicGains Posted - 4 days ago

$BCLI Big upside here if they stick the landing on their next trials. Holding firm and buying on dips!

User Image HUMBL4Now Posted - 4 days ago

$BCLI haven’t checked on this in a week, it good to see the increase in SP!!! Do we think it’s only in anticipation for the meeting on the 30th? Or is this thing starting to make moves!?

User Image bballandstocks Posted - 5 days ago

$BCLI this has 4.27 million float per yahoo finance, is that accurate/current data?

User Image funnymoney90210 Posted - 5 days ago

$BCLI This is going up. Trust me

Analyst Ratings
Maxim Group Buy Jul 11, 24
Maxim Group Hold Sep 28, 23
Maxim Group Buy Mar 31, 23
Maxim Group Buy Feb 5, 21
HC Wainwright & Co. Buy May 15, 18
Maxim Group Buy Aug 17, 17